A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Finance & markets
A pharma giant is moving past one patent cliff — but another is already looming
Policy desk, National Trade News (2026-10-30): Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. Primary source: original at CNBC Top News (cnbc.com).